Clinical Trials Directory

Trials / Completed

CompletedNCT02648958

Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations

Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Unilateral Total Knee Replacement - a Randomized, Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
68 (actual)
Sponsor
Yonsei University · Academic / Other
Sex
All
Age
20 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Ischemia reperfusion injury causes the release of free oxygen radicals. The selective alpha2-receptor agonist, dexmedetomidine, has an inhibitory effect on inflammatory responses during ischemic injury. The aim of this study is to evaluate the effect of dexmedetomidine on inflammatory responses during ischemia-reperfusion injury in skeletal muscle.

Conditions

Interventions

TypeNameDescription
DRUGDexmedetomidineThe dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.
DRUGnormal salineThe control group received the normal saline infusion

Timeline

Start date
2016-01-01
Primary completion
2017-07-31
Completion
2017-07-31
First posted
2016-01-07
Last updated
2018-06-13

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02648958. Inclusion in this directory is not an endorsement.

Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations (NCT02648958) · Clinical Trials Directory